Amgen in collaboration with Novartis Pharma AG has developed Aimovig™, a novel therapeutic approach to prevent a migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in a migraine.
Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick® autoinjector, and does not require a loading dose. Some patients may benefit from a dosage of 140 mg once monthly.
Aimovig resulted in significant reductions in monthly migraine days and use of acute migraine medications compared to placebo.
These effects on monthly migraine days have been shown to be sustained for up to 15 months in an ongoing open-label extension study in an episodic migraine (four to 14 headache days per month).
Aimovig’s efficiency and tolerability have been assessed in more than 3,000 patients. The most common adverse reactions such as injection site reactions and constipation were found in clinical studies.
Aimovig offers self-administration with proven efficacy across a spectrum of patients, including in those who have previously tried other preventive therapies without success.
Aimovig™ (erenumab-aooe) received FDA approval for the prevention of a Migraine in patients experiencing four or more Migraine days per month.
